Ivonescimab meets key goal in biliary tract cancer trial, partners report
Akeso and Summit Therapeutics announced that their bispecific antibody ivonescimab achieved a primary endpoint in a Phase 3 study for biliary tract cancer, marking a success beyond lung cancer. The trial was conducted exclusively in China, and the companies touted the result as a significant milestone for the drug candidate.
Ivonescimab, a bispecific antibody developed by Akeso and Summit Therapeutics, has now shown promise in a second cancer type. The Phase 3 trial, run entirely in China, met its primary goal for patients with biliary tract cancer—a rare and aggressive malignancy with limited treatment options. This result extends the drug's potential beyond its earlier focus on lung cancer, where it had already generated interest.
The companies framed the outcome as a key milestone, though the data remain unpublished and unverified by outside regulators. Biliary tract cancers are notoriously difficult to treat, and any new therapy that improves outcomes would fill a significant gap. The China-only scope also raises questions about how results might translate to broader global populations, but the achievement itself marks a notable step for the drug candidate.
If confirmed, this result could offer a new treatment avenue for patients with biliary tract cancer, who currently face few effective therapies. It may also accelerate regulatory reviews and expand ivonescimab's commercial potential beyond lung cancer. However, the trial's single-country design and lack of peer-reviewed data mean the true impact remains uncertain. Oncologists and patient groups may watch for further studies, while investors could react to the news. Ultimately, the benefit hinges on whether the drug proves safe and effective in larger, more diverse populations.